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Updates on Blood Glucose Monitoring 
in Patients with Diabetes
Dr. Elaine HUI
MBBS, MD (UK), MRCP (UK)
Clinical Assistant Professor, University of Hong Kong
Introduction 
Blood glucose monitoring is integral to assessing 
glycaemic control, which in turn, correlates with risks 
of diabetic complications. Various methods to monitor 
blood glucose help to guide clinical decision making in 
different scenarios, enabling minute-by-minute, day-
by-day of up to average 3-monthly analyses of glucose 
control. HbA1c and fingerstick capillary blood glucose 
monitoring are the main tools for assessment of average 
and daily blood glucose levels. Technological advances 
have improved the accuracy of continuous glucose 
monitoring and insulin pump devices, becoming a step 
closer to an ‘artificial pancreas’ combining real-time 
glucose sensing, analysis of insulin dose calculation and 
insulin delivery.
HbA1c as a measure of glucose control
Glycated haemoglobin A1c (HbA1c) is commonly 
used as a measure of average glucose control over the 
preceding 2 – 3 months. It reflects the average glycaemic 
exposure that informs us of the risks of microvascular 
and macrovascular complications, with approximately 
10 - 40% risk reduction for each 1% reduction in mean 
HbA1c level1;2. 
Limitations of HbA1c
In patients with similar HbA1c values, the diabetic 
complication rates are significantly lower in patients 
treated with intensive glucose control, compared to 
standard therapy, suggesting additional factors, such 
as glycaemic variations, may play a role in the risk of 
diabetic complications3. HbA1c alone does not reflect 
day-to-day glycaemic variation and rates of hypo- and 
hyperglycaemia. Patients could have the same HbA1c, 
but with frequent episodes of hypo- and hyperglycaemia 
or with stable glycaemia. HbA1c measurements are also 
invalid in conditions, such as haemoglobinopathies, 
that affect red cell survival. Therefore, additional 
glucose measuring tools are needed to identify aspects 
of glycaemic dysregulation and guide therapeutic 
management. 
Self-monitoring capillary blood glucose 
Checking capillary glucose levels by pricking a fingertip 
with an automatic lancing device and measuring the 
blood sample with a glucose meter is routinely used 
for self-monitoring blood glucose (SMBG). It provides 
assessment of day-to-day glycaemic variations. As a 
glucose measuring tool to guide insulin adjustment, 
SMBG is effective in lowering HbA1c among type 1 
and type 2 diabetes patients treated with insulin4;5. In 
type 2 diabetes patients not on insulin, SMBG can still 
provide feedback on the impact of dietary and lifestyle 
interventions on blood glucose control, and as a tool for 
patient education. 
Indications for self-monitoring capillary blood 
glucose6:
1) Newly diagnosed diabetes
2) Patients on insulin treatment
3) Patients on oral agents to assess hypoglycaemia 
4) During activities, such as driving or intense 
exercise, to ensure safety
5) During intercurrent illness
6) Diabetes during pregnancy
7) For assessment of glucose control resulting from 
changes in medications or lifestyle modifications
Timing and frequency of self-monitoring blood 
glucose:
1) In type 1 diabetes patients and those on intensive 
insulin regimens (i.e. multiple-dose insulin 
injections or insulin pump therapy), SMBG 
should be done at least once before every meal; 
occasionally at bedtime; when hypoglycaemia is 
suspected and after hypoglycaemic treatment; and 
before activities such as driving. Post-prandial 
blood glucose monitoring (2-hour post-meal) 
would be helpful in individuals whose pre-meal 
glucose values are within target, but HbA1c levels 
are suboptimal7. 
2) In type 2 diabetes, patients on oral agents or 
less intensive insulin regimens (e.g. once daily 
injection), the frequency of SMBG will depend 
upon individual needs and target goals (Table 1).
3) In pregnant women with type 1,  type 2 or 
gestational diabetes, 7-point SMBG profiles (pre-
meal, 1 or 2-hour post-meal, and bedtime) have 
been recommended throughout pregnancy6. 
Advances in blood glucose meters
Blood glucose meters using fingerstick testing have also 
developed novel ways to tailor specific needs of diabetes 
patients. For instance, some glucose meters:
• Provide glucose testing as well as blood ketone 
testing (e.g. Freestyle Optium Xceed) that is useful 
to ketosis-prone diabetes patients
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• Transmit glucose readings wirelessly (e.g. Bayer 
Contour® Link) to an insulin pump to make insulin 
dosing easier
• Feature voice commands (e.g. Clever Chek) for the 
visually-impaired
• Connect glucose readings to mobile phones 
(e.g. iBGStar®) to keep track of glucose values, 
carbohydrate intake and insulin dosage 
Table 1. Recommended glycaemic targets for adults with diabetes
Measure of 
glucose control
Type of 
diabetes
Recommended 
target
Further considerations 
HbA1c Type 1 or 2 < 7.0% Higher individualised 
targets for patients with:
- long duration of 
diabetes
- limited life expectancy
- elderly
- comorbidities
- advanced microvascular 
and macrovascular 
complications
- hypoglycaemic 
unawareness
Pre-
conception 
< 7.0% (ADA)7
< 6.1% (NICE)13
Aim for as close to 
normal as possible 
Capillary 
blood glucose 
monitoring 
Type 1 or 
Type 2 on 
MDI or insulin 
pump 
Before meals:
3.9 – 7.2 mmol/L
2-hr after meals or 
bedtime:
< 10 mmol/L
Aim to achieve target 
without significant 
hypoglycaemia
Critically ill 
in-hospital 
patients on 
insulin
Target range:
7.8 – 10.0 mmol14
Gestational 
diabetes
5th International 
workshop 
conference on 
GDM15
Before meals:
< 5.3 mmol/L
1-hr after meals:
< 7.8 mmol/L
2-hr after meals:
< 6.7 mmol/L
NICE13
Before meals:
3.5 – 5.9 mmol/L
1-hr after meals:
< 7.8 mmol/L
Continuous glucose monitoring 
With recent technological advances, continuous glucose 
monitoring (CGM) devices can detect trends and track 
patterns in patients with rapidly fluctuating glucose 
levels, sounding an ‘alarm’ when glucose rises or drops 
beyond pre-selected levels. This is particularly helpful in 
type 1 and type 2 diabetes patients with hypoglycaemic 
unawareness or nocturnal hypoglycaemia8.  In a 
multicentre trial from the Juvenile Diabetes Research 
Foundation, CGM was effective in lowering HbA1c 
levels among type 1 diabetes patients who were 25 years 
or older, but not in younger patients9.  A meta-analysis 
has also shown that CGM lowered HbA1c by 0.26% 
compared to SMBG, without any difference in severe 
hypoglycaemia10. 
Indications for continuous glucose monitoring:
1) The UK National Institute for Health and Clinical 
Excellence (NICE) recommends the use of CGM in 
children or young adults with type 1 diabetes or 
any adult treated with insulin, who has repeated 
hypo- and hyperglycaemia, or hypoglycaemic 
unawareness, unresponsive to conventional insulin 
dose adjustment6.
2) In the 2013 Standards of Medical Care in diabetes, 
the American Diabetes  Associat ion (ADA) 
recommends CGM as a supplemental tool to SMBG 
in those with hypoglycaemic unawareness and/or 
frequent hypoglycaemic episodes, in addition to 
its use to lower HbA1c in selected adults (>25 years 
of age) with type 1 diabetes on intensive insulin 
therapies7.
 
CGM devices use a small sensor inserted under the skin 
to detect glucose levels in the interstitial fluid, which 
then generates glucose readings every 5 minutes, 24 
hours a day. Modern sensors can be used for up to 7 days 
before requiring replacement. A transmitter sends data 
about glucose levels via radio waves from the sensor to a 
wireless monitor. There are currently three commercial 
CGM device manufacturers: Medtronic (Northridge, 
CA), DexCom (San Diego, CA), and Abbott Diabetes Care 
(Alameda, CA). Each manufacturer provides softwares 
to download and analyse the CGM data. A standardised 
electronic summary has been proposed to include the 
following statistical and graphical parameters11, allowing 
clinicians to interpret the CGM data and make purposeful 
clinical decisions, and to provide instant visual feedback 
to patients (Figure 1). 
Validated parameters to aid CGM data 
interpretation:
1) Measures of glucose variability: 
a) Standard deviat ion (SD)  quantif ies  glucose 
distribution within 24 hours (as intra-day SD) or 
between different days (as inter-day SD). It is easy 
to compare results and is frequently used in CGM 
analysis reports. However, it assumes a normal 
glucose distribution, which does not always 
happen in real-world glucose monitoring.
b) Coefficient of variation (CV) equals to (100 x SD)/
means of observations and is a reliable marker for 
glucose variability, but is limited in clinical use as 
it is not easily displayed visually.
c) Interquartile range (IQR) is not dependent on a 
normal distribution, and is clinically useful as a 
measure of glucose variability in relation to the 
time of day, time of meal or insulin dose.
2) Glucose target ranges
a) ‘Within target range’ can be expressed as the % of 
glucose readings in a pre-set range or hours per 
day in that specified range
b) ‘Above target range’ reflects the % of hyperglycaemic 
readings
c) ‘Below target range’ reflects the % of hypoglycaemic 
readings 
3) Episodes of hypoglycaemia and hyperglycaemia, 
according to the levels of severity
Although the interstitial fluid glucose values used in 
CGM are highly comparable to the capillary blood 
glucose used during fingerstick testing, CGM still 
requires capillary blood glucose testings at certain time 
points for sensor calibration. There is a lag time between 
the interstitial fluid and the capillary blood glucose, 
which becomes clinically significant when the capillary 
blood glucose rises/falls sharply. Nonetheless, modern 
CGM devices have greatly reduced the lag time and 
improved on sensor accuracy.
Medical BulletinVOL.18 NO.10 OCTOBER 2013
    7
Sensor-augmented insulin pump
Sensor-augmented insulin pump works towards an 
‘artificial pancreas’ model by combining real-time CGM 
(RT-CGM) with an insulin pump (figure 2). It integrates 
the use of RT-CGM in the analysis of glucose patterns 
and calculation of insulin basal rates, insulin duration 
of action, insulin to carbohydrate ratios and correction 
factors. In type 1 diabetes patients with baseline 
HbA1c of 8.3% ± 0.5, patients on sensor-augmented 
insulin pumps had greater reduction in HbA1c (7.5%), 
compared to multiple daily insulin injection group 
(8.1%) (P<0.001), without significant difference in severe 
hypoglycaemia rates (13.31 cases per 100 person-years 
vs. 13.48 per 100 person-years, P=0.58)12. Limitations 
to sensor-augmented pump therapy include: constant 
attachment of 2 subcutaneous devices (sensor and 
pump); risk of cellulitis at attachment sites; and pump 
failure, in which reversal to subcutaneous insulin 
injections is required. 
Figure 2. a and b. A sensor-augmented insulin pump 
system (adapted from Bergenstal et al.12)
Figure 1. An electronic summary (figure 1 a) and a graphical summary (figure 1b) of a 4-day continuing glucose 
monitoring data (adapted from Bergenstal et al.11) 
Medical Bulletin VOL.18 NO.10 OCTOBER 2013
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Resident Specialist, Division of Endocrinology & Diabetes
Department of Medicine & Therapeutics, Prince of Wales Hospital
Head, Division of Endocrinology & Diabetes
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Introduction
Type 2 diabetes mellitus (T2DM), a state of relative 
insulin insufficiency, was previously usually diagnosed 
in middle-age adults; however, increasing numbers 
of young adults/children in high risk populations 
are being diagnosed1. The “ominous octet” (Figure 1) 
orchestrating the pathophysiology of T2DM, proposed 
by Ralph DeFronzo in the 2009 American Diabetic 
Association (ADA) Banting Lecture, formed the basis 
of pharmacological intervention of T2DM. Insulin 
resistance is typically present for some time before 
the diagnosis.  Initially, euglycaemia is maintained 
as long as beta (β)-cells compensate for the resistance 
by secreting higher amounts of insulin. Overtime, the 
insulin level declines due to the reduced number of 
β-cells and their compromised secretory ability2.  Studies 
have shown a ~50% or greater decrease in maximal β-cell 
function at diagnosis of T2DM3,4.  
Figure 1.  The Ominous Octet depicting the 
Pathophysiology of Type 2 Diabetes Mellitus
Adapted from Defronzo5 
The global burden of T2DM is rising, especially in the 
Asia-Pacific region, and is exerting a significant impact 
in both public health and socioeconomic aspects.  In 
Hong Kong, 1 in 10 adults will have diabetes6.  In 
the China Mainland, the prevalence is predicted to 
rise from 9.3% in 2011 to 12.1% in 2030, and the adult 
diabetic population is expected to grow from 90.0 to 
129.7 millions7.  Emerging evidence suggests that for the 
same degree of body weight, Asians have considerably 
higher body fat, especially visceral fat compared to 
Caucasians8-10, giving rise to the “metabolically obese” 
phenotype.  Asians with T2DM have predispositions 
for renal complications and strokes as compared to 
Caucasians11. Therefore, physicians in Hong Kong 
not only need to familiarise themselves with diabetic 
treatment according to the latest  international 
guidelines, but to strive for the optimal management 
of the local diabetic populations paying particular 
attention to how local diabetics differ from those from 
the rest of the world12.  This brief update will discuss 
the profiles of various oral antidiabetic medications, 
predominantly, for T2DM.
Treatment Target of Type 2 Diabetes 
Mellitus
The goals of pharmacological therapy for T2DM 
are to reduce the symptoms of hyperglycaemia and 
the long term complications. It is well known that 
glycaemic control reduces the risks for microvascular 
complications, including neuropathy, retinopathy, and 
nephropathy5,13-15_ENREF_11. Premature mortality 
from cardiovascular diseases (CVD) is increased in 
patients with T2DM16.  However, it remains unclear 
whether intensive glycaemic control reduces that risk17. 
Glycaemic target put forward by current international 
guidelines is glycated haemoglobin (HbA1c) ≤6.5-
7%.  Individualisation has been a key emphasis stating 
that tighter targets are set for younger and healthier 
individuals, while looser targets are set for older 
patients and/or those who have comorbidities or are 
hypoglycaemia prone11,18. Maintenance of long term 
glycaemic control without deleterious side effects (such 
as hypoglycaemia, weight gain) has become one of the 
priority considerations. Evidence for CVD and cancer 
safety is also prudent as many medications are taken for 
almost lifelong. Smoking cessation and optimisation of 
related risk factors such as blood pressure, lipids, and 
body weight are of equal importance.  
This article has been selected by the Editorial Board of the Hong Kong Medical Diary for participants in the CME programme of the Medical 
Council of Hong Kong (MCHK) to complete the following self-assessment questions in order to be awarded 1 CME credit under the programme 
upon returning the completed answer sheet to the Federation Secretariat on or before 31 October 2013.
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Pharmacological Therapy for Type 2 
Diabetes Mellitus
Initiation of appropriate pharmacotherapy (multiple 
many a time), would be interpreted as an adjunct to 
proactive lifestyle management giving the progressive 
nature of T2DM. Treatment inertia is commonly 
observed, particularly in general practice, with undue 
delay in commencement and escalation of combination of 
pharmacological therapies. In particular, the β-cell failure 
which begins earlier and is more severe than previously 
thought argues for the need for early and aggressive 
treatment to preserve remaining β-cell function and to 
limit further disease progression 2. Currently available 
oral antidiabetic drugs include biguanide, sulfonylurea 
(SU), meglitinide, thiazolidinedione, alpha(α)-glucosidase 
inhibitors, and dipeptidyl peptidase-IV (DPP-IV) 
inhibitors. The most recently developed oral agent is 
sodium glucose co-transporter 2 (SGLT2) inhibitors. 
Table 1 summarises the profiles of these oral antidiabetic 
medications.
Biguanide
Metformin is the only biguanide available. It lowers 
blood glucose predominantly by suppressing hepatic 
gluconeogenesis and may also increase glucose uptake 
and utilisation in skeletal muscle. It does not stimulate 
appetite and is therefore weight neutral and sometimes, 
it even promotes a slight weight loss. Metformin 
does not cause hypoglycaemia if used alone. With its 
inexpensive cost and evidence of long term safety, 
metformin has become the first line treatment for 
many patients diagnosed with T2DM. Unwanted side 
effects of metformin are dose related gastrointestinal 
disturbances (eg: anorexia, diarrhoea, nausea), which are 
Table 1.  Profiles of Oral Antidiabetic Medications for Glycaemic Control in Patients with Type 2 Diabetes Mellitus.
Biguanide 
(Metformin)
Sulfonylurea/ 
Meglitinide
Thiazolidinedione
(Pioglitazone)
α-glucosidase 
inhibitor
DPP-IV 
inhibitor
SGLT2 inhibitor
Hypoglycaemia 
risk
Neutral Moderate to 
severe/mild
Neutral Neutral Neutral Neutral
Effect on weight Neutral/Slight loss Gain Gain Neutral Neutral Loss
GI side effects Moderate Neutral Neutral Moderate Neutral Neutral
Bone loss Neutral Neutral Moderate Neutral Neutral No information
CVD risk Beneficial ? Neutral Neutral Neutral Neutral
CHF risk Neutral Neutral Moderate Neutral Neutral Neutral
Use in renal 
impairment
Dosage adjustment 
required 
Not to use in eGFR 
<45 ml/min/1.73m2
Dosage 
adjustment 
required 
Contraindicated in 
advanced stage
No dose adjustment 
required
Not to use in 
eGFR < 25 ml/
min/1.73m2
Dosage adjustment 
required (except 
for linagliptin)
Dosage adjustment 
required Not to 
use in eGFR <45 
ml/min/1.73m2
Use in hepatic 
impairment
Contraindicated in 
advanced stage
Contraindicated in 
advanced stage
No dose adjustment 
required
No information No dose 
adjustment 
required for mild 
to moderate stage 
Limited 
information 
for advanced 
stage (except for 
linagliptin)
No dose 
adjustment 
required for mild 
to moderate stage 
Contraindicated in 
advanced stage
Drug cost Low Low Relatively high Relatively high High High
HbA1c lowering 
potency as 
monotherapy  (%) 
†20,21
1.0-2.0 1.0-1.5 0.5-1.4 0.5-0.9 0.5-0.8 0.5-0.7
Data from Garber 19,  Ismail-Beigei 20, and Clar 21 et al
DPP-IV denotes dipeptidyl peptidase-IV
SGLT2 denotes sodium glucose co-transporter 2
† In real life practice, the HbA1c lowering potency depends very much on initial HbA1c and whether an appropriate combination is used
usually but not always self-limiting. Lactic acidosis is a 
rare but potentially fatal complication, and metformin 
should therefore not be given to patients with advanced 
renal or hepatic impairment, uncontrolled heart failure, 
or shock, as these patients are predisposed to lactic 
acidosis due to reduced drug elimination or reduced 
tissue oxygenation.  Metformin is contraindicated in 
patients with chronic kidney disease (CKD) stage 3B, 4, 
or 5, but can be used cautiously with reduced dose in 
mild to moderate CKD (estimated glomerular filtration 
rate (eGFR) ≥ 45 ml/min/1.73m2)11.  Long-term use of 
metformin may interfere with absorption of vitamin B12 
which might contribute to megaloblastic anaemia and 
the progression of diabetic neuropathy22. Although the 
screening frequency for vitamin B12 level and its cost-
effectiveness remain to be elucidated, baseline tests at 
the initiation of metformin and at intervals of about 
1-2 years are recommended as metformin induced 
vitamin B12 deficiency is treatable with vitamin B12 
replacement23.    
Sulfonylurea and Meglitinide
Gliclazide, glipizide, glimepiride, and glibenclamide 
are the most widely used SUs, while repaglinide and 
nateglinide are the two meglitinides available. High-
affinity receptors for SUs are present on the potassium-
adenosine triphosphate (KATP) channels in the β-cell 
plasma membranes, and these drugs reduce the 
potassium permeability of β-cells by blocking the 
KATP channels, causing depolarisation and calcium 
entry, resulting in insulin secretion. SUs improve 
glycaemic control and reduce the risk of microvascular 
complications5,13-15 at a relatively low drug cost, but 
this has to be balanced against the risk of weight gain, 
hypoglycaemia, and the possible adverse effects on the 
cardiovascular system17.  Another significant drawback 
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of SUs is their exhaustive effects on β-cell function 
which drive the β-cells to fail earlier24. It should also 
be remembered that the dosage should be reduced 
in patients with renal and/or hepatic impairment to 
prevent hypoglycaemia.  
Meglitinides, although pharmacologically distinct 
from the SUs, also stimulate the release of insulin from 
β-cells25. The clinical efficacy of meglitinide monotherapy 
is similar to that of the SUs26-28.  In 2010, the Nateglinide 
And Valsartan in Impaired Glucose Tolerance Outcomes 
Research (NAVIGATOR) study group reported that 
among patients with impaired glucose tolerance (IGT) 
and CVD or CVD risk factors, nateglinide, as compared 
with placebo, in addition to lifestyle modifications, did 
not reduce the incidence of diabetes or CVD outcomes. 
However, nateglinide did not increase adverse CVD 
effects, although the risk of hypoglycaemia is increased 
and the mean weight loss was lower as compared to the 
placebo group29. The advantage of the other meglitinide, 
repaglinide, over SUs is the ability to use it safely in 
patients with decreased eGFR or renal failure without 
concern for hypoglycaemia since it has little renal 
clearance30.
Thiazolidinedione
Thiazolidinediones increase insulin sensitivity by 
binding to a nuclear receptor called the perioxisome 
proliferator-activated receptor-gamma (PPARγ), 
which occurs mainly in adipose tissue, but also in 
muscle and the liver. They mediate differentiation of 
adipocytes, increase lipogenesis, and enhance uptake 
of fatty acids and glucose. Pioglitazone is now the 
only thiazolidinedione available in Hong Kong. It is 
not associated with hypoglycaemia and the additional 
effects of pioglitazone on the lipid profile (decreases in 
triglycerides and increases in high density lipoprotein 
(HDL)) has once made this drug popular31. However, 
in view of an epidemiological study conducted in 
France which suggested an increased risk of bladder 
cancer with pioglitazone, the drug was suspended in 
France and Germany since 201132. After considering 
further epidemiological evidence, the European 
Medical Agency (EMA) concluded that there is a 
small increased risk (relative risk ranging from 1.12 
to 1.33) of bladder cancer in diabetic patients treated 
with pioglitazone, particularly in those treated for 
the longest durations (more than 2 years) and with 
the highest cumulative doses (more than 28000mg)33. 
The United States Food and Drug Administration 
(FDA) also issued a safety communication in 2011 
recommending physicians not to use pioglitazone in 
patients with active bladder cancer and to use it with 
caution in patients with a prior history of bladder 
cancer. This unresolved controversy will continue 
to evolve with more long term data available from 
various retrospective data base analyses.  Rosiglitazone 
has been discontinued in Hong Kong and Europe 
since 2010, and is highly restricted in the United States 
owing to persistent concern about an increased risk 
of myocardial infarction based on meta-analyses of 
observational studies34,35.  Both thiazolidinediones can 
cause weight gain, fluid retention, and heart failure36. 
Both have been shown to be associated with low-
trauma fractures in men and women37.  In addition, the 
cost of thiazolidinediones is relatively high.
Alpha-glucosidase inhibitor  
Acarbose, an inhibitor of intestinal α-glucosidase, 
delays carbohydrate absorption,  reducing the 
postprandial increase in blood glucose. Common 
adverse effects are related to its main action and consist 
of flatulence, bloating, abdominal pain, and diarrhoea.
Like metformin, it does not cause hypoglycaemia and is 
weight neutral.  While postprandial hyperglycaemia is 
a strong independent predictor for the development of 
T2DM, a preliminary study has shown that treatment 
of patients with IGT with acarbose is associated 
with a significant reduction in insulin resistance 
with a decrease in postprandial hyperglycaemia and 
hyperinsulinaemia38.  Therefore, although acarbose has 
never been a commonly used antidiabetic medication, 
it can be used in addition to lifestyle modifications 
to delay development of T2DM in patients with IGT 
with up to 25% relative risk reduction39.  Results from 
the Acarbose Cardiovascular Evaluation (ACE Trial), 
a large-scale, double-blind, multicentre trial, would 
elucidate the cardiovascular effects of acarbose in 
Chinese subjects with IGT.  The cost of this medication 
is moderate.   
Dipeptidyl peptidase-IV inhibitors
The fact that oral glucose has a greater stimulatory 
effect on insulin secretion than intravenous glucose 
illustrates the importance of the incretin effect, of 
which glucagon-like peptide-1 (GLP-1) is one of the 
several important gastrointestinal peptides involved40. 
Sitagliptin, vildagliptin, saxagliptin, and linagliptin, are 
the DPP-IV inhibitors available in Hong Kong.  They 
inhibit DPP-IV, an enzyme expressed on the surface of 
most cell types that deactivates a variety of peptides 
including GLP-1, thereby potentiating the incretin 
effect from GLP-141. They are generally well tolerated 
without the risk of hypoglycaemia when used alone 
and are weight neutral.  DPP-IV inhibitors only produce 
a modest reduction in HbA1c, but have enhanced 
synergistic effects when combined with metformin. 
Recently, DPP-IV inhibitors are suspected to increase 
the risks of pancreatitis and pancreatic cancer from 
epidemiological and retrospective database analyses. 
A causal relationship has not yet been established, but 
both the EMA and FDA are evaluating its safety42. We 
will have much better insight on these unresolved safety 
concerns from several ongoing DPP-IV cardiovascular 
endpoint trials involving a total of >50,000 patients with 
prospective systematic collection of safety data apart 
from looking at the adjudicated clinical end points. 
Dose adjustment is necessary for patients with renal 
and/or hepatic impairment except for linagliptin, which 
is primarily excreted un-metabolizsed via the bile and 
gut43. The cost of these DPP-IV inhibitors is high.
Sodium glucose co-transporter 2 inhibitors    
The search for new oral treatments for T2DM is 
ongoing and the latest addition is the SGLT2 inhibitors. 
Dapagliflozin and canagliflozin are now available in 
Europe and the United States respectively and are 
expected to be available in Hong Kong soon. SGLT2 
is expressed in the proximal tubule of kidneys and 
mediates reabsorption of ~90% of the filtered glucose 
load. SGLT2 inhibitors promote the renal excretion of 
glucose and thereby lower blood glucose. They are only 
administered once daily. Another merit with SGLT2 
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inhibitors is that they can either be used as monotherapy 
or in combination with any other antidiabetic drugs 
(oral or injectable) since their mechanism of action 
is independent from the aetiology of development 
of diabetes or the mechanisms that protect against 
hyperglycaemia. The lowering effect of HbA1c is similar 
to that of DPP-IV inhibitors and is modest (~ 0.8%).  The 
most common side effects are vaginal yeast infection and 
urinary tract infection44. Other beneficial effects from 
SGLT2 inhibitors include a reduction in body weight 
(-1.88 to -2.85 Kg), blood pressure (-1.3 to -7.2 mmHg), 
and a lower risk of hypoglycaemia (3.4% versus 39.7% 
when using dapagliflozin with metformin as compared 
to using glipizide with metformin)21,45.  Long term data 
on microvascular or cardiovascular outcomes are not yet 
available. The cost of SGLT2 inhibitors is high.  
Management algorithm
With the ever growing list of antidiabetic drugs available 
on the market, choosing the right drugs for the right 
patients can be a challenge to everyday practice. The 
American Association of Clinical Endocrinologists 
(AACE) has issued a new T2DM management algorithm11 
in May this year with the aim to assist physicians in 
making the best choice and has been summarised in 
Figure 2.  Lifestyle modifications remain the cornerstone 
of diabetic management for each and every patient. 
Although the management of comorbidities of type 
2 diabetic patients, including blood pressure, lipids, 
body weight, albuminuria, psychosocial factors etc…
just to name a few, are beyond the scope of this article, 
it is necessary to remember that successful patient 
management requires a holistic approach.
Figure 1.  The Ominous Octet depicting the Pathophysiology of Type 2 Diabetes Mellitus
Adapted from Garber _ENREF_1819
 Conclusion
Type 2 diabetes mellitus is a chronic, heterogeneous, 
and progressive disease defined by the presence of 
hyperglycaemia with insulin resistance and inadequate 
β-cell function being the major culprits. The burden of 
T2DM in Hong Kong is staggering.  The overall aim 
of diabetic management is to minimise complications 
while avoiding hypoglycaemia and weight gain. Oral 
antidiabetic medications remain the initial therapy for 
the majority of patients. The choice of drugs would best 
be made together by the physicians and patients after 
comprehensive information about the effectiveness 
and safety of medications is communicated. Last but 
not least, lifestyle modifications remain the essential 
foundation in the management of every patient. 
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MCHK CME Programme Self-assessment Questions
Please read the article entitled “A Brief Update on Oral Antidiabetic Medications” by Dr. Kitty KT CHEUNG and 
Dr. Francis CC CHOW and complete the following self-assessment questions. Participants in the MCHK CME 
Programme will be awarded CME credit under the Programme for returning completed answer sheets via fax (2865 
0345) or by mail to the Federation Secretariat on or before 31 October 2013. Answers to questions will be provided 
in the next issue of The Hong Kong Medical Diary. 
1. Studies have shown that by the time Type 2 Diabetes is diagnosed, about 50 % or more of beta cell mass is lost. 
2. Asians have considerably less body fat, especially visceral fat compared to Caucasians.
3. Metformin can be used cautiously with a reduced dose in mild to moderate chronic kidney disease.
4. The possible side effects of sulfonylurea include the risk of weight gain, hypoglycaemia, and the possible 
adverse effects on cardiovascular system.
5. There is a small increased risk of colon cancer in diabetic patients treated with pioglitazone, particularly in 
those treated for long durations and with high cumulative doses.
6. Acarbose can be used in severe renal failure patients.
7. DPP-IV inhibitors are suspected to increase the risk of pancreatitis and pancreatic cancer from 
epidemiological and retrospective database analyses.
8. SGLT2 inhibitors promote the renal excretion of glucose and thereby lower blood glucose by acting on the 
distal tubule of the kidney.
9. The most common side effects of SGLT2 are vaginal yeast infection and urinary tract infection.
10.  Among currently available oral antidiabetic drugs, sulphonylurea and biguanide have the highest HbA1c 
lowering potency.
Questions 1-10: Please answer T (true) or F (false) 
ANSWER SHEET FOR OCTOBER 2013
Answers to September 2013 Issue
Please return the completed answer sheet to the Federation Secretariat on or before 31 October 2013 for 
documentation. 1 CME point will be awarded for answering the MCHK CME programme (for non-specialists) self-
assessment questions.
Screening for CA Prostate
1 4 82 5 93 76 10
1. F T T T F T FF F F4. 8.2. 5. 9.3. 7.6. 10.
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Introduction 
The burden of type 2 diabetes mellitus (T2DM) is 
increasing rapidly around the world. The prevalence 
is expected to more than double over the next 20 years, 
and it is estimated that there will be 440 million people 
suffering from T2DM by 2030.1 In China Mainland , the 
prevalence of diabetes will rise from 4.5% (43.2million) 
in 2010 to 5.8% (62.6million) in 2030.1 Type 2 diabetes 
remains a leading cause of cardiovascular diseases, 
end-stage renal failure, blindness, amputations, and 
hospitalisations. The United Kingdom Prospective 
Study (UKPDS) has demonstrated that intensive 
glycaemic control effectively reduces microvascular 
complications by 25% to 76%, although its role in 
reducing cardiovascular risks remains less certain.2 
Treatment of  diabetes should begin with diet , 
exercise and weight reduction. In the absence of 
contraindications, metformin should be initiated together 
with lifestyle modifications.3 Oral hypoglycaemic agents 
become less effective as beta cell function declines. 
The therapeutic options for patients who have failed 
lifestyle modifications & metformin include adding (1) 
a second oral drug, or (2) an injectable agent, including 
insulin or glucagon-like peptide-1 (GLP-1) analogues. 
There is no consensus on which is the best treatment 
to add. However, insulin is preferred when marked 
hyperglycaemia is present, especially when HbA1c is 
>8.5%. Many patients eventually require insulin as the 
beta cell function deteriorates. GLP-1 based therapy, on 
the other hand, has the advantage of weight reduction 
and a low risk of hypoglycaemia. This article will focus 
on insulin and GLP-1 analogues in the management of 
T2DM.  
INSULIN
Insulin therapy has evolved considerably since its 
discovery in the 1920s. Significant improvements 
have been made in the purification, production and 
formulation of insulin. Insulin was initially extracted 
from the pancreases of cattle and pigs, but since the 
1980s, human insulin has been manufactured using 
recombinant DNA technology.4 Insulin therapy aims 
to replicate endogenous basal and stimulated insulin 
release to suppress hepatic glucose production and 
minimise post-prandial glucose excursions respectively. 
Several types of insulin preparations are available. The 
onset, peak and duration of action of commonly used 
insulins in Hong Kong are summarised in Table 1. 
Intermediate-acting and long-acting preparations are 
used as the basal (fasting) component, and short-acting 
insulin and rapid-acting insulin analogues are used as 
the bolus (prandial) component. 
Human insulin 
( i )  Intermediate-act ing  human insul in : 
Protaphane HM®, Humulin N®   
The only conventional intermediate-acting human 
insulin currently in clinical use is neutral protamine 
Hagedorn (NPH) insulin. It is a suspension of crystalline 
zinc insulin combined with protamine, which allows 
for a delay in absorption from the subcutaneous tissue 
resulting in up to 20 hours of action. However, NPH 
exhibits a pronounced peak 5 – 7 hours after injection, 
leading to an increased risk of nocturnal hypoglycaemia 
if injected in the evening (Table 1). There are also wide 
inter- and intra-individual variabilities in action as NPH 
must be evenly suspended before administration. NPH 
is still widely used nowadays due to its low cost, and 
its ability to be mixed with regular human insulin in a 
premixed preparation4. 
(ii) Short-acting human insulin: Actrapid HM®, 
Humulin R®   
Regular human insulin has a delayed onset of action (30 
– 60 minutes after injection), relatively late peak effect (2 
– 4 hours after injection) and longer duration of action 
(6 – 8 hours) compared with the endogenous insulin 
secretion that occurs after meal (Table 1). Regular 
human insulin needs to be administered 30 minutes 
before meal, which is inconvenient for many patients. 
It may also lead to early post-prandial hyperglycaemia 
and late hypoglycaemia.4  
Human insulin analogues 
Insulin analogues are produced by recombinant 
bioengineering techniques. The human insulin molecule 
is modified by amino acid substitutions, inversions or 
additions, so that these analogues can better simulate 
endogenous insulin secretion. Long-acting insulin 
analogues have been modified to possess a stronger 
ability to self-associate, thus resulting in a longer 
duration of action. On the other hand, rapid-acting 
insulin analogues have been altered to impede self-
aggregation, so that they have a faster onset of action.  
(i) Long-acting insulin analogues: Glargine 
(Lantus®), Detemir (Levemir®)  
Glargine and detemir were developed to mimic the 
physiological profile of basal insulin, aiming at a long 
and steady action. Both long-acting analogues are 
relatively peakless, have an onset of action within 1 – 
3 hours of injection, and a duration of up to 24 hours. 
(Table 1) Both glargine and determir demonstrate 
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less inter-individual variability in absorption when 
compared with NPH insulin. For patients with T2DM, 
both glargine (once daily) and detemir (twice daily) 
were shown to achieve similar HbA1c when compared 
with NPH insulin, but the risk of hypoglycaemia, in 
particular nocturnal hypoglycaemia, was lower with 
glargine & determir.5-7 A comprehensive review of 
glargine and detemir found no clinical differences in 
their efficacy and safety. Detemir was often required as 
twice daily injections at higher doses, but resulted in 
less weight gain. Glargine was injected once daily, and 
resulted in less injection site reactions.8  
(ii) Ultra long- acting analogues: Insulin 
degludec (Tresiba®), PEGylated Insulin lispro  
Insulin degludec is a novel ultra long-acting basal insulin 
that forms multihexamers on subcutaneous injection. It 
has recently been approved by the European Medicines 
Agency (EMA), but declined by the US Food and Drug 
Administration (FDA), owing to concerns regarding a 
potential increase in cardiovascular risks. Degludec has 
a half-life of longer than 24 hours, and a long duration of 
action in excess of 40 hours. Degludec has been shown 
to have lower within-patient variability than glargine.9 
Compared with glargine and determir, degludec has been 
shown to have comparable efficacy in glycaemic control, 
but a lower incidence of hypoglycaemia. Degludec also 
has the ability to be mixed with other insulins, which 
cannot be done using glargine or determir.10
PEGylated Insulin lispro (LY2605541) is another ultra 
long-acting insulin under development. Phase 2 clinical 
trials have been completed and a series of phase 3 
trials are underway.11 By embedding insulin lispro in a 
polyethylene glycol chain, the duration of action of the 
drug is substantially extended. Steady-state profile data 
show that it has a flat profile and over 24 hours duration 
of action.  
(iii) Rapid-acting insulin analogues: Lispo 
(Humalog®), Aspart (Novorapid®), Glulisine 
(Apidra®)  
For many patients with T2DM, basal insulin is often 
adequate for good glycaemic control, as endogenous 
insulin secretion will control post-prandial excursions. 
However, for some patients with longer duration of 
T2DM or those with difficult control, premeal boluses 
may be required. Lispro, aspart and glulisine are 
commercially available as rapid-acting insulin analogues 
for use as bolus insulins. They have been structurally 
altered to impede self-aggregation into multimeric 
complexes. Hence, they have a faster onset of action (10 – 
30 minutes after injection), a peak of action (30minutes – 
2 hours) and a shorter duration of action (3 – 4 hours) in 
comparison with regular human insulin. (Table 1) They 
simulate the physiological meal-stimulated insulin release 
more accurately, but do not demonstrate significant 
improvements in glycaemic control in T2DM in terms of 
HbA1c when compared with regular human insulin in 
clinical studies.12 However, from a practical point of view, 
rapid-acting insulin analogues allow greater convenience 
and flexibility in the timing of injections. They can be 
given immediately before meals, as opposed to 30 – 45 
minutes before meal for regular human insulin.     
 
Premixed insulin preparations 
Most premixed insulin preparations contain an 
intermediate-acting insulin, together with either a 
regular human insulin (premixed human insulin), 
or rapid acting insulin analogue (premixed insulin 
analogue). (Table 1) Premixed insulin preparations have 
the obvious advantage of delivering basal and prandial 
insulin in a single injection, and are more effective in 
reducing postprandial glucose and HbA1c levels than 
basal insulin.13 However, they are less flexible, and 
are associated with a higher risk of hypoglycaemia.13 
Premixed insulin analogues and premixed human 
insulin are similar in efficacy in terms of glycaemic 
control (decreasing fasting glucose and HbA1c) and 
the incidence of hypoglycaemia, but premixed insulin 
analogues are superior in controlling postprandial 
glucose excursions with less intra-subjection variations.13
    
Table 1: Pharmacokinetic parameters of commonly used 
insulins in Hong Kong
Action Profile (hours)
Insulin Trade name Manufacturer Onset Peak Duration 
Rapid-acting
Lispro Humalog Eli Lilly
0.2 – 0.5 0.5 – 2 3 – 4Aspart Novorapid Novo Nordisk
Glulisine Apidra Sanofi-Aventis
Short-acting
Regular Humulin R Eli Lilly 
0.5 – 1 2 – 4 6 – 8Actrapid HM Novo Nordisk
Long Acting
Glargine Lantus Sanofi-Aventis 
1 – 3 No peak Up to 24Determir Levemir Novo Nordisk 
Premixed human insulin: NPH/ regular
70%/30% Humulin 70/30 Eli Lilly
0.5 – 1 3 – 12 Up to 24 Mixtard 70/30 Novo Nordisk 
Premixed insulin analogues 
Neutral protamine lispro/ Lispro
75%/25% Humalog mix 
75/25
Eli Lilly
0.2 – 0.5 1 – 14 24 
50%/50% Humalog mix 
50/50
Eli Lilly
Insulin aspart protamine/ Aspart
70%/30% Novolog Mix 
30
Novo Nordisk 
0.2 – 0.5 1 – 14 24
50%/50% Novolog Mix 
50
Novo Nordisk
Adapted from CA Borgono, B Zinman. Insulins: Past, Present and 
Future. Endocrinol Metab Clin North Am 2012;41:6.4
GLUCAGON-LIKE PEPTIDE-1 
ANALOGUES
 
Glucagon-like peptide-1 is secreted from the L-cells 
of the small intestine following ingestion of a meal. 
GLP-1 is responsible for the incretin effect, in which 
oral glucose has a greater stimulatory effect on insulin 
secretion than intravenous glucose load. The incretin 
effect is diminished in T2DM. GLP-1 stimulates 
insulin secretion from the pancreatic beta-cells, and 
inhibits glucagon secretion from the alpha-cells, both 
in a glucose-dependent manner. It also slows gastric 
emptying, and stimulates satiety by binding to its 
receptor in the hypothalamus. GLP-1 has a short half-life 
of one to two minutes due to degradation by the enzyme 
dipeptidyl peptidase 4 (DPP-4).14 As a glucose-lowering 
agent, GLP-1 needs to be given as a continuous infusion 
and therefore has limited therapeutic potential.14 GLP-1 
analogues have been developed so that they are resistant 
to DPP-4 degradation and can restore the incretin effect 
in T2DM. GLP-1 analogues have no intrinsic risk of 
hypoglycaemia as the stimulation of insulin secretion 
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occurs in a glucose-dependent manner.15 They are 
currently approved in combination with metformin 
and/or sulphonylurea in patients who fail to reach 
therapeutic goals.14 
(i) Exenatide (Byetta®) 
Exenat ide  has  a  hal f  l i fe  of  2 .4  hours ,  and is 
administered subcutaneously as twice-daily injections. 
It reduces HbA1c by 0.8 – 1.1%, and weight loss of 1.5 
– 3.0 kg in 30 weeks. Weight loss is associated with 
improvement in blood pressure and lipids. Nausea is 
the most common side effect, and it can be reduced 
by starting with a small dose first. It is recommended 
to start at 5 microgram twice daily, and increase to 
10 microgram twice daily after 4 weeks. Exenatide is 
eliminated mainly by the kidneys and should not be 
used in patients with creatinine clearance of less than 
30ml/min. Rare cases of acute pancreatitis have been 
reported with the use of exenatide and FDA had issued 
a warning to the label in 2007.14
(ii) Liraglutide (Victoza®) 
Liraglutide has a longer half-life of 13.5hours, and is 
administered as an once daily subcutaneous injection. 
To decrease the gastrointestinal side effects like nausea 
and vomiting, it should be started at 0.6mg daily for 
one week, and then stepped up to 1.2mg daily. The 
dosage can be increased to 1.8mg daily if blood glucose 
level is still above the goal. In combination with various 
oral drugs, liraglutide reduces HbA1c by 1.3% – 1.5%. 
Liraglutide also causes significant weight loss and 
lowers the systolic blood pressure by 2 – 6mmHg. 14 
(iii) Exenatide once weekly (Bydureon®)  
In exenatide once weekly formulations, exenatide is 
encapsulated in biodegradable polymeric microspheres. 
After injection of the microspheres, degradation starts 
resulting in sustained release of exenatide molecules, 
and subsequent absorption from the subcutaneous 
tissue. A steady plasma exenatide level is reached after 
6 – 7 weeks of treatment. In type 2 diabetic patients 
treated with metformin, exenatide once weekly produces 
greater HbA1c reduction of 1.5 – 1.9% than exenatide 
twice daily (1.0 – 1.5%) and other oral hypoglycaemic 
agents (0.9 – 1.2%). In addition, exenatide once weekly 
results in weight loss of 2.3 – 3.6kg, and improvement 
in blood pressure and lipid profiles. Gastrointestinal 
side effects, like nausea and vomiting, are reduced 
by about one-third when compared with twice daily 
formulations.  A direct comparison between liraglutide 
and exenatide once weekly showed a greater reduction 
in HbA1c and in weight, but more nausea and/
or vomiting with liraglutide.16 Several other once-
weekly long-acting GLP-1 analogues (e.g. taspoglutide, 
albiglutide, semaglutide) are in development.17      
Conclusion 
Type 2 diabetes mellitus is a chronic disease with 
progressive decline in pancreatic beta-cell function, 
eventually leading to insulin deficiency and failure 
of many patients in achieving satisfactory glycaemic 
control. Oral insulin secretagogues become less effective 
as pancreatic beta-cell function declines, and insulin 
is the preferred second-line medication when patients 
have marked hyperglycaemia. Patients frequently 
decline to start insulin due to fear of needles and self-
injection. They may also perceive starting insulin 
therapy as a failure to control their diabetes, and that 
the disease is becoming more severe. Physicians should 
spend time and resources to educate patients on the 
chronic nature of the disease, and that insulin is a very 
effective mode of treatment. With the help of diabetes 
nurse educators, patients can usually learn to administer 
insulin confidently.
Weight gain and fear of hypoglycaemia are also 
significant barriers in initiation of insulin. GLP-1 
analogues, on the other hand, are an attractive option of 
therapy as they cause weight loss and have no intrinsic 
risk of hypoglycaemia. They are also simpler to use than 
insulin as they do not require titration of dosage based on 
home blood sugar monitoring. The UK National Institute 
for Health and Clinical Excellence (NICE) guidelines 
recommend a GLP-1 analogue as an alternative to 
insulin, especially when obesity is a problem.18 There 
are, however, many unanswered questions regarding the 
long term benefits and risks in the clinical use of GLP-1 
analogues in T2DM. Data on cardiovascular safety and 
pancreatitis risk will become available once ongoing large 
outcome trials with GLP-1 analogues are completed.19 
A patient-centred approach has been advocated in the 
latest Position Statement jointly released by the American 
Diabetes Association and the European Association 
for the Study of Diabetes. The choice of anti-diabetic 
agents, including insulin and GLP-1 analogues, has to be 
individualised for each patient, considering the efficacy, 
risk of hypoglycaemia, effect on weight, cost and major 
side effects of each medication. 3
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Burden of diabetes and associated 
comorbidities
Over 60% of global deaths are due to chronic diseases 
defined by the World Health Organization such as 
diabetes, heart disease, respiratory disease and cancer. 
Amongst these 4 chronic diseases, diabetes plays a 
causal role in the pathogenesis of cardiovascular-renal 
diseases and multiple morbidities. In the Emerging Risk 
Factor Collaborative Study, people with diabetes had 1.3 
to 3 fold increased risk of vascular, cancer, non-vascular 
non-cancer deaths, the latter mainly due to renal failure, 
sepsis, hepatobiliary and mental diseases1. In support 
of these findings, since 1995, the CUHK-PWH Diabetes 
Care and Research Team has established a Diabetes 
Registry which has enrolled more than 10,000 patients 
with 2-5% of these subjects experiencing one or major 
events including heart failure, stroke, coronary heart 
disease, cancer and death on a yearly basis2.
Table 1: A validated risk score to predict diabetes 
developed in Hong Kong Chinese population (ref 7). 
Depending on the setting and demographics of the 
subjects, 10- 50% of subjects with a risk score≥12 had 
diabetes on 75 gram oral glucose test. 
Predictors Risk score
Age
≥40-50 versus <40 3
≥50-60 versus <40 6
≥60-70 versus <40 10
≥70 versus <40 12
Body mass index (kg/m2)
≥23-25 versus <23 2
≥25-30 versus <23 4
≥30-35 versus <23 7
≥35 versus <23 8
Other risk factors
Hypertension (yes versus no) 3
Dyslipidaemia (yes versus no) 3
Family history of diabetes (yes versus no) 2
Gestational diabetes (yes versus no) 2
Detection of diabetes for early 
intervention
Despite these devastating consequences, there is a 
large body of epidemiological and randomised clinical 
trial data showing that diabetes3,4 and its associated 
complications and comorbidities are preventable, 
treatable and affordable especially if these preventive 
strategies are implemented during the early stage of 
disease5,6. While population-based screening of diabetes 
is generally not recommended, targeted screening using 
known risk factors and simple risk scores7,8 (Table 1) 
based on family history, history of cardiovascular 
disease,  hypertension,  dyslipidaemia,  obesity, 
gestational diabetes and polycystic ovarian syndrome 
give a high yield of positive cases who will benefit from 
early intervention. Furthermore, targeted screening in 
high risk young subjects (e.g. those with family history) 
is considered particularly cost-effective due to their high 
lifetime risk for complications9. 
Figure 1. A proposed flow chart for detection of high risk 
subjects for diabetes and follow up action
Provided that the assays of glycated haemoglobin 
(HbA1c) are compatible with international standards, 
the combined use of fasting plasma glucose and 
HgA1c can be used effectively to detect people with 
undiagnosed diabetes10 (Figure 1). The majority of 
these subjects with prediabetes or early diabetes 
will benefit from structured lifestyle modifications 
including a balanced diet, increased physical activity, 
reduced consumption of sugar sweetened beverages 
and snacks, cessation of smoking, stress management, 
sleep hygiene, avoidance of further gain in body 
weight and losing 3-5 kg of body weight if overweight/
obese11 (Figure 2). While lifestyle modifications 
are effective in reducing the risk of diabetes and 
its complications, it is important to recognise that 
diabetes is primarily a beta cell disorder and as such, 
many of these subjects may eventually require some 
medications for glucose control to preserve the beta 
cell structure and function12.
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Figure 2. Relationships between baseline lifestyle factors 
and residual lifetime risk of diabetes at age 45 years 
in 20,915 men and 36,594 women in the US Physician 
Health Survey and Women’s Health Survey followed 
up for a mean of 22.6 years. Healthy lifestyle factors 
included never smoking, moderate alcohol consumption 
(1 drink per day), regular exercise (2 times per week of 
vigorous exercise), healthy diet, and normal weight 
(BMI<25 kg/m2) (Ref 11).
Detection of diabetes and associated 
risk factors and complications
The biggest challenge in diabetes management is clinical 
inertia, delayed intervention, frequent default and poor 
treatment compliance, in part due to the silent and non-
urgent nature of the disease13,14. These challenges are 
particularly relevant to young to middle aged people 
who often have multiple commitments and do not feel 
the urgency to control these silent conditions resulting 
in default or delayed intervention15. These subjects with 
young-onset of disease are growing in number and 
account for 20% of our diabetic populations who are at 
high risk for complications during their prime of life with 
enormous impacts on society, individuals and families16.
Improve diabetes care by reorganising 
workflow and delegating responsibilities
There are now local and international protocols of 
diabetes care and recommended treatment targets17,18. 
However to achieve these objectives, changes in the 
clinic environment and training of paramedical staff 
are needed to enable the patients to undergo periodic 
comprehensive assessment for risk stratification. 
The latter is the first  and most important step 
towards informed decisions and personalised care. 
From a patient’s perspective, regular feedback on 
individualised risk profiles and trends of treatment 
targets (notably, HbA1c, blood pressure(BP), LDL-
cholesterol, body weight) will raise disease awareness, 
motivate behavioural changes and reinforce positive 
changes. From a doctor’s perspective, these performance 
indexes are important in monitoring the effectiveness of 
intervention and for continuous quality improvement 
purposes19,20. 
In a recent meta-analysis involving nearly 100,000 
patients, quality improvement strategies targeting at 
the patient and system including patient education, 
task sharing and case management are associated 
with the greatest reduction in HbA1c, BP and LDL-
cholesterol21. These improvements are expected to 
reduce cardiovascular and renal complications by 20-
50% in the long term22.
Doctor as a mentor, manager and 
monitor in delivery of diabetes care
Diabetes is common and affects 5-10% of the population 
in most developed and developing societies23. In 
most surveys, 50% of these affected subjects were 
undiagnosed24 and that amongst the diagnosed, only 
50% were treated and amongst those treated, less than 
10% had attained all 3 ABC treatment goals (A1c<7%, 
BP<130/80 mmHg and LDL-C<2.6 mmol/l)25. In most 
clinic settings, an average doctor only had 6 minutes 
of contact time with each of his/her patients26. Yet, in 
patients with diabetes who need to understand the 
‘what, why and how’ of the condition in order to be 
motivated and learn how to change lifestyle, improve self 
care, return for regular follow up and often, take long 
term medications, contact time with regular support, 
reinforcement and reminders is the key determinant to 
predict sustained behavioural changes27. 
Thus, despite the amassing body of knowledge regarding 
the preventable and treatable nature of diabetes, the 
reality is that changing the behaviour is difficult and 
remains one of the biggest challenges in translating 
evidence to practice28. Given the growing number of 
patients and short contact time with doctors, a more 
affordable and sustainable solution is needed to improve 
the efficiency and effectiveness of efficacious treatments 
and strategies, taking incentives and practicality into 
consideration29. In this connection, most of the hospital 
and primary care systems are not designed to manage the 
lifelong and pluralistic needs of a middle-aged subject 
with diabetes over a period of 40 years or more. Amongst 
these challenges, the systematic collection, integration 
and communication of health information to both 
care providers and patients, essential for good clinical 
practice, is particularly daunting.
During the last two decades, many clinical trials have 
been conducted to test the efficacy of novel treatments 
and interventions in controlled settings. While 
conclusions from some of these studies have been 
included in treatment guidelines, few experts have 
highlighted the impact of clinical trial settings on the 
quality of care. Detailed analysis of these megatrials 
showed consistent data that patients managed in these 
controlled settings characterised by the use of a protocol 
with predefined processes and treatment targets, care 
coordinator (often a research nurse) and a trial monitor, 
had the best chances of achieving multiple treatment 
targets30. 
Leveraging on these observations and with increasing 
calls by experts to use scientific methods to develop and 
evaluate multidimensional strategies to improve care in 
real practice31, it is indeed feasible for doctors to change 
their clinic environment and transfer their knowledge 
to other health care professionals, notably nurses, and 
use protocols to guide nurses to collect information for 
doctors to make informed decisions, upon which nurses 
can be used to reinforce treatment compliance and 
clarify misconceptions.
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Furthermore, it is now recognised that 20-50% of patients 
with diabetes have negative emotions, including stress, 
anxiety and depression which may adversely affect 
treatment compliance and self care. While some of 
these patients may need pharmacological interventions, 
many of them will benefit from motivational interviews 
by nurses and/or empathetic listening and emotional 
support from their peers32,33. 
Given the complexity of these care protocols (Figure 
3) and increasing demands from payers on doctors 
to report rates of adherence to recommended care 
processes and attainment of treatment targets within 
cost affordability34,35, there is a growing need for 
doctors to learn how to use management principles and 
technologies whereby they can leverage the expertise 
of other co-workers and partners to deliver these care 
protocols with documentation of intermediate indexes 
and clinical outcomes.
Figure 3. Recommended flow chart in 
diabetes management by the Western Pacific 
Declaration on Diabetes (www.wpdd.org).
Using collaborative care and 
information technology for quality 
improvement
In 1995, due to limited manpower and large patient 
volume, the CUHK-PWH Diabetes Care and Research 
Team developed an integrated care model where 
we used trained nurses to perform comprehensive 
assessments including blood and urine tests as well as 
eye/feet examination, in accordance to international 
guidelines, for risk stratification every 12-18 months, 
followed by triage to primary care, non-diabetes 
specialist and diabetes specialist care36. Using this 
Registry which had enrolled more than 10,000 patients 
and accrued over 5000 clinical events, we were able to 
develop and validate a series of risk equations to predict 
cardiovascular and renal events with 70-90% sensitivity 
and specificity. In a series of projects, we were also able 
to use a collaborative approach, augmented by care 
protocols, to reduce the risk of cardiovascular-renal 
complications and all-cause deaths in type 2 diabetic 
patients with or without complications by 50-70%37,38 
(Figure 4). 
In 2007, we incorporated these risk equations and care 
protocols into the web-based disease management 
programme (Joint Asia Diabetes Evaluation, JADE, 
Programme) with built in risk engines, care protocols, 
decisions support and personalised reports to patients 
and doctors (www.adf.org.hk). Our preliminary 
analysis showed that 20-40% of patients had significant 
improvement in ABC targets and psychological well-
being after enrolling in the JADE Programme with 
personalised reports and decision support. Thus, by 
training a dedicated nurse to collect these information 
guided by structured templates, who serves as a liaison 
between doctors and patients, doctors can be relieved 
of the burden in performing these tasks and concentrate 
on reviewing the patients’ risk profiles, making clinical 
decisions and supporting co-workers to implement 
holistic care, in a more efficient and effective manner39,40 
(Figure 5). 
Figure 4. The effects of collaborative care augmented 
by protocols with predefined processes and treatment 
targets on clinical outcomes including death and 
cardiovascular-renal events in Hong Kong Chinese 
patients 1) with hypertension and type 2 diabetes (Ref 
36, upper panel) and 2) with type 2 diabetes and chronic 
kidney disease (Ref 37, lower panel) (excerpts from 
www.wpdd.org). 
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Figure 5. Task sharing between doctors and nurses in 
quality improvement programme for diabetes care with 
ongoing monitoring and evaluation. 
SBGM-self blood glucose monitoring
Conclusion
Diabetes is a major public health care burden and 
personal disaster, if not diagnosed, managed or 
controlled. There are now proven strategies to prevent 
the onset of diabetes and its complications, which will 
save life and money in the long term. However due 
to the non-urgent nature of these silent conditions, 
these preventive strategies proven to be efficacious 
in controlled settings are often not implemented in 
real practice due to reasons such as lack of motivation 
to change, care fragmentation, lack of mandates and 
insufficient incentives. 
While many parties, including the Government, now 
recognise the need to use multisectorial strategies 
including the use of mandates, incentives and audits to 
create an environment conducive to a healthy lifestyle 
and practice of preventive medicine41, doctors are in the 
prime position to take the first step to empower their 
subordinates to change the clinic setting, improve the 
workflow and document these processes and outcomes, 
which will not only benefit their patients but also bring 
out the best of their clinical expertise. 
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The City Gardener 
Dr. Jenny LEE
Hon. Secretary, Hong Kong Specialist Medical Association
I like plants in general, but Hong Kong is a city of 
concrete and construction sites, where any private 
outdoor space, however tiny, seems to be a luxury. The 
solution is to create planting space yourself, wherever 
you may be. True success depends on the type of plants 
chosen. In Hong Kong, the environment chooses the 
plants, not us. Let me share with you some of my office 
plant favourites that look delicate but are in actual fact 
quite hardy.
African Violet
This is an all-time favourite of many office ladies and 
there are cheap varieties (down to $10/plant) available 
in the Flower Market. The trick is to make it flower all 
year round and that may take some experimenting. I 
found that they like small pots with just a little amount 
of soil (about 1/2 cupful), and weekly liquid fertiliser . If 
given a large pot they tend to spend most of their time 
expanding roots and refuse to flower. They will flower 
regularly if given at least 3-4 hours of sunshine each day, 
but the ambient temperature must be cool, so an air-
conditioned room with a south-facing windowsill will 
be best. Artificial lighting with a small florescent reading 
light over the plant for most time of the day will be fine 
too, but less effective. Care must be taken while watering, 
because any water droplets on the hairy leaves will 
cause light to refract and burn the leaf. Although I have 
heard of propagation by seeds, African violets are most 
conveniently (and without any cost too) propagated by 
leaf cuttings. Put the stem of a cut leaf into a small bottle 
of clean water and roots will appear in about 2-3 weeks, 
followed by tiny green leaves. Transplant this gently into 
a small pot of soil and it can generate into 3 or 4 new 
plants, ready to bloom in about 4-5 months’ time, from 
the day of the cutting. I found a special set of plastic pots 
with a water stand very useful, although a bit plain. They 
can be bought from an African violet specialty upstairs 
shop at the Flower Market. All you need now is to find 
a friend with a nice African violet plant with the kind of 
flowers you like, and ask for the donation of a leaf.
Purple Clover - 紫花酢醬草
( Oxalis corymbosa )
I bought my purple clover while still in medical school, 
and that was two decades ago. It is still growing and 
has propagated (by me) to the homes of many of my 
friends and colleagues. Because my first plant came 
with a tag “from Holland”, and it already cost over 
$20 in those days, I thought it should be a very delicate 
plant. However, it remained weak throughout its first 
years and often lost all the leaves while placed indoors 
in an air-conditioned office in a shaded corner. One day 
it dawned on me that it looked like the wild clover in 
my backyard except for the size of its leaves and colour. 
It has flourished since then in a pot and on the ground 
without much care and fertilisers but with plenty of sun. 
The ones on my windowsill in the office are also doing 
well, but it will need at least bright indirect light from 
the window. The “roots” or underground stems are able 
to remain dormant for many weeks even without any 
leaves, so do not throw it away too soon. It prefers soil 
on the dry side, and requires very little if any fertiliser 
(it is a wild plant). There are small bell-shaped pink 
flowers all year long that usually last only one day. I 
twist off the stems of withered leaves and flowers just 
to be tidy. This does not harm the plant. With time the 
underground stems/ roots will multiply and you will 
have to replant or give them away. The purple leaves that 
come in different shades and patterns close up at night 
naturally like an umbrella, so do not worry about that.
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Orchids
Orchids are particularly popular around the Chinese 
New Year. Apart from the traditional peach blossoms 
they are nearly the only other type of flowering plant 
I will get in the Flower Market around the CNY. Many 
of my friends did not know that they are perennial 
plants and would throw them away after the flowers 
are gone. Given minimal care and spare, orchids are 
actually one of the easiest to care for flowering plants 
I know of. All one needs to do is to cut down the 
flowering stem after the last flowers have withered, get 
some new moss (from any plant shop, but try to get 
the type from New Zealand), cut off the old dried up 
roots (if you are not sure, skip this step) and replant 
the orchid in the same pot. For lazy people who do 
not want to do “ramet” (分株 ) or spend much time in 
tidying up an overgrown plant, the best orchids will be 
the “butterfly orchid”. The Butterfly orchid has only a 
few very stationary big leaves per plant (occasionally 
wiping to clean the surface for good photosynthesis 
will be deeply appreciated by your orchid). There may 
be 2-3 new leaves per year and 1 or 2 old leaves may 
dry up at the bottom after the flowering, but otherwise 
they do not change much throughout the year. If kept 
indoors in a controlled environment, they will require 
only 1-2 watering per week (try to keep the moss moist 
on most days). Being flowering plants with very slow 
metabolism I usually give them very small infrequent 
“meals” of  fertilisers in pellets (mine are grey), about 5-6 
dispersed on the moss every 2-3 months. I use inorganic 
fertilisers because the organic ones will get mouldy 
and smell in the moist moss. The pellets will release 
the fertilisers into the moss when being watered. By the 
end of 9 months there should be 1 to 2 new flowering 
shoots, ready to bloom again for the CNY. Orchids do 
best if given 3-4 hours of diffuse sunlight or daylight per 
day. My DOM in my department took several appalling 
looking orchids back to her office last Spring. With 
the minimal care described above she has beautiful 
blooms this CNY. The leaves will be burned by direct 
hot sunlight in the summer so please take care. Again 
orchids are very tough - I have resurrected orchids even 
at the stage when there was only 1 leaf left, so do not 
throw them away prematurely.
Hong Kong climate and your plants
Hong Kong has a very hot and humid summer, but both 
the purple clover and orchids can survive outdoors very 
well. My clover can survive both the summer sun and 
rain very well. They may “shrink” a bit in the winter but 
they will revive in spring. I hang my butterfly orchids 
under a tree, with some protection from the direct 
summer sunlight. Although they look delicate they 
have survived Black rain and typhoon no. 10 with no 
damage. Check the moss for rotting roots if the rainfall 
is constant.  However, these meaty roots can rot if there 
is too much moisture around. With all plants, rotate the 
pot periodically if the light source is always from one 
side (e.g. a window). Otherwise, you may end up with a 
“torticollis” plant!
Enjoy!
Dermatological Quiz
Dr. Ka-ho LAU
MBBS(HK), FRCP(Glasg, Edin), FHKCP, FHKAM(Med)
Private dermatologist
This 55-year-old man noticed these net-like eruptions at his lower limbs for a 
few months which were persistent but asymptomatic. On further questioning, 
he complained of multiple joint pain with active arthritis at his fingers 
symmetrically.
Questions:
1.  What is your clinical diagnosis or differential diagnoses?
2.   How will you manage this man?
Fig.1: Skin lesions at lower limbs
Dr. Ka-ho LAU
(See P.36 for answers)
Dermatological Quiz
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Medical Nutrition Therapy in Type 2 Diabetes
Ms. Tina CHAN
Registered Dietitian (UK)
Dietetic Department, Our Lady of Maryknoll Hospital
Member of the Hong Kong Practising Dietitians Union
Type 2 diabetes results from a progressive insulin 
secretory defect on the background of insulin resistance1, 
which is associated with obesity; and Chinese with 
body mass index ≥ 25 kg/m2 have an increased risk 
of type 2 diabetes2. Medical nutrition therapy (MNT) 
is commonly known as the groundwork in diabetes 
management and it has been well documented that 
MNT can improve glycaemic control, enhance clinical 
and metabolic outcomes, and reduce the hospitalisation 
rates3,4,5,6. MNT has been shown to reduce glycated 
haemoglobin (HbAlc) by an average of ~1% to 2%3, 7. 
MNT is effective at any time in the disease process 
but it appears to have its greatest effect in lowering 
HbAlc at the initial stage of diagnosis3. Outcomes of 
the MNT interventions are evident by 6 weeks to 3 
months and on-going evaluations should be done.  Type 
2 diabetes is a progressive disease where the β-cell 
function may deteriorate over time. Therefore, if no 
clinical improvement in glycaemic control is evident 
upon follow up, inclusion or adjustment of blood 
glucose lowering medication(s), including insulin, may 
be needed in combination with MNT to achieve the 
goals3.  Thus, at least one follow-up appointment is 
recommended annually to diabetic patients to reinforce 
lifestyle changes, as well as to evaluate and monitor 
outcomes. 
Although following a diet is commonly known as one 
of the most challenging parts of diabetes management, 
physicians may not have access to a registered dietitian 
(RD) at their clinics to provide the necessary support 
for diabetic patients. Given the importance of MNT 
in diabetes management, this article aims to provide 
recommendations for enhancing nutrition care for type 
2 diabetic patients.
Maintaining cooperation approach
A consistent and coordinated multidisciplinary 
approach by the physician, dietitian and nurses can 
enhance the patient’s cooperation and compliance 
to MNT. Though an appreciation of the dietary 
management of diabetes by a physician is substantial, 
detailed instructions of MNT should be delivered by a 
dietitian. It is strongly recommended by the American 
Diabetes Association, which stated in the Standards of 
Medical Care that “ individuals who have prediabetes or 
diabetes should receive individualised MNT as needed 
to achieve treatment goals, preferably provided by a 
registered dietitian (RD) familiar with the components 
of diabetes MNT1”.
Dietitians are practising in different sectors, including 
private practices, community services, Department 
of Health clinics, and hospitals under the Hospital 
Authority. A list of accredited dietitians in Hong Kong 
can be found on the website of the Hong Kong Dietitians 
Association (http://www.hkda.com.hk/). Under normal 
circumstances, a medical doctor's referral is required 
for patients to consult dietitians in the Department of 
Health clinics and HA hospitals. 
Dietitians will conduct a detailed nutritional assessment 
based on the patient's anthropometric measurements, 
medical history, medications, laboratory results, diet 
history, and social history. Dietitians will then be able to 
provide individualised MNT including prescribing meal 
plans tailored to patients' needs. Patients' progresses 
and treatment outcomes are documented and reported 
to the referral sources. Constant reinforcement of 
dietary advice usually results in enhanced cooperation 
and better blood sugar control. 
Meal Planning
The diet for people with type 2 diabetes is qualitatively 
the same as that of the non-diabetic counterparts (Figure 
1. Food Guide Pyramid). There is no generic way to 
define a 'diabetic diet' and to prescribe a meal plan fit 
for all diabetic patients. On the contrary, MNT and 
meal planning should be individualised by taking into 
consideration the individual's age, type and duration 
of diabetes, concurrent medications, treatment goals, 
personal values, food preferences, culture, lifestyle, 
economic status, activity levels, abilities, and readiness 
to change7. 
Figure 1. Food Guide Pyramid 10
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Healthy eating, body weight control and regular 
physical activities are important objectives in people 
with type 2 diabetes. Since an estimated 80 to 90% of 
people with type 2 diabetes are overweight or obese7, it 
is vital to encourage any degree of weight loss. 
A modest weight loss of 5 to 10% of initial body weight 
can substantially improve insulin sensitivity and 
glycaemic control, as well as to relieve hypertension 
and dyslipidaemia in people with type 2 diabetes8. 
Increased physical activity and overall calorie reduction 
will decrease body weight. A reduction in total energy 
intake and/or increased energy expenditure, leading to a 
total of about 500 calories energy deficit per day should 
result in a weight loss of 0.5kg per week. Dietitians can 
help patients to identify and minimise sources of hidden 
energy intakes, educate them to make healthy food 
choices, and assist them in meal planning.
Carbohydrates 
Carbohydrate foods have a direct impact on the blood 
glucose levels. Numerous studies have shown that 
equivalent carbohydrate amounts of sugars and starches 
produce similar responses in glycaemia9. 
An initial MNT that focuses on carbohydrate control 
and meal timing consistency may be most important 
for glucose control. Therefore, control of portion 
sizes is an important message to convey to patients. 
It is recommended that carbohydrate foods should 
contribute to 45-60% of total daily energy intake7. 
A low carbohydrate diet is not ideal for weight loss. 
Rather, the key issue for weight control is overall caloric 
reduction. Moreover, restricting carbohydrate intake to 
less than 130g per day is not recommended as glucose is 
the primary fuel for the brain and central nervous system 1.
Patients are recommended to eat a controlled amount 
of carbohydrate foods consistently at main meals and 
snack times. Thus, dietitian will teach patients about 
carbohydrate exchanges and how to read food labels. 
Table 1 shows a variety of carbohydrate foods in different 
portion sizes that all contain 10g of total carbohydrate. 
Table 1. Carbohydrate choices: 10g carbohydrate serving sizes10: 
Food Serving size
Grains, breads, 
cereals
Rice 1/5 bowl* or 1 heaped table 
spoon
Bread 1/2 slice (large) or 1 slice 
(small)
Oatmeal 2 level table spoons (raw) 
or 
1/2 bowl* (cooked)
Cornflakes 1/4 bowl*
Weetabix 1 piece
Milk or 
alternatives
Skimmed milk 1 glass (250ml)
Plain yoghurt 1 cup (150ml)
High calcium soy 
milk
1 class (250ml)
Fruits Apple/ orange/ 
banana
1/2 pieces
Grapes 5 pieces (large) or 
10 pieces (small)
Blueberries 1/2 cup
Note: * bowl 300ml volume
Glycaemic Index
The Glycaemic index (GI) classifies carbohydrate foods 
according to their impact on blood glucose levels (high: 
GI >70, medium: GI 55-70, low: GI <55). Consuming 
a low-GI diet was shown to sustain improvements in 
glycaemic control and HDL-cholesterol compared with 
a high cereal fibre diet over 6 months11.  Low GI foods 
include barley, pasta, chapatti, beans, nuts, lentils, milk, 
yogurt, and apples12. 
In practice, it is recommended that people with diabetes 
should have high fibre, low GI carbohydrate food at 
each meal. However, there are many factors that may 
affect blood glucose surge, e.g. the ripeness of the food, 
degree of cooking and processing, and physical form of 
the food. It is advised to check pre- and post-meal blood 
glucose levels to assess the impact of particular meals 
and to determine if choosing lower GI alternatives can 
improve blood glucose levels. 
Dietary Fibre
It is recommended to consume 25-30 g of dietary fibre 
from a wide variety of foods (14 g fibre per 1000kcal) 
with special emphasis on soluble fibre (7-13 g)3 (Table 2. 
Examples of fibre and soluble fibre content of common 
food). Evidence suggests that the additional of soluble 
fibre (e.g. egg plant, okra, oat products, beans, psyllium, 
and barley) slows gastric emptying and delays the 
absorption of glucose in the small intestine and thus 
improves post-meal blood glucose control13. 
Moreover, diets high in total and soluble fibre are shown 
to further reduce total cholesterol by 2% to 3% and LDL 
cholesterol up to 7%14. Thus, carbohydrate foods which 
are rich in fibre and have a low energy density are the 
basis of an optimal dietary plan.
Table 2. Total fibre content and soluble fibre of common food:
Food Total fibre 
content (g)
Soluble fibre 
content (g)
Oatmeal 1/4 cup (35g) 3.5 1.5
Apple (1 small) 2.8 1
Banana (1 small) 2.2 0.6
Orange (1 small) 2.9 1.8
Broccoli (1/2 cup) (cooked) 2.4 1.2
Carrot (1/2 cup) (cooked) 2.0 1.1
Spinach (1/2 cup) (cooked) 1.6 0.5
Kidney beans (1/2 cup) (cooked) 7.9 2.0
Source: Harvard University Health Services. Fibre Content of Foods in 
Common Portions. May 2004.
Dietary Fat
As people with diabetes have a 2 to 3 times higher risk 
of having coronary artery disease in comparing to non-
diabetics, it is recommended that dietary fat should 
contribute to 20-30% of total daily energy intake, with 
total cholesterol less than 200 mg/d, saturated fat <7% 
of total calories, and minimal trans fat intake7,15. This is 
beneficial for lipid profile control and weight control. 
The National Cholesterol Education Program (NCEP) 
recommends that monounsaturated fats can range up 
to 20% of total calories intake15. It can be found in olive 
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oil, canola oil, nuts, and avocado. Omega-3 fatty acids 
like fish oil and flaxseed oil have been shown to lower 
triglyceride levels and inhibit platelet aggregation. 
Thus, it is generally recommended to consume at least 2 
servings of fatty fish per week. 
Patients are advised to avoid full fat dairy products, 
processed/fatty meat and poultry skin, and limit oil 
used in cooking. Patients are also recommended to 
choose lower fat dairy products and ask the butcher for 
a lean cut and have the skin removed when shopping 
for meats. Patients will also be educated that there are 
hidden fats in some carbohydrate-containing foods 
(e.g. butter in pineapple bun / cake, palm oil in instant 
noodles, deep-fried foods etc.), and their consumption 
can lead to unintended weight gain and increased LDL-
cholesterol level.
Dietary Protein
Patients with type 2 diabetes with normal renal function 
are advised to have protein intake contributing to 15-
20% of the daily energy intake, which aligns with the 
recommendation for the general population3. Though 
protein has a very little effect on blood glucose levels 
and an acute effect on insulin secretion3, patients are 
advised to take the fat content and cooking method into 
consideration when consuming protein-rich foods.  A 
vegetable source of proteins (e.g. beans and pulses, tofu) 
is very low in fat. 
Sugars
Added sucrose, like all carbohydrates, raises the 
blood glucose. Thus, there is no need to eliminate it 
completely from the diet, and could be included as 
part of the meal plan for diabetic patients (up to 10% 
of total daily energy intakes7).  However, alternative 
sweeteners may still have a role in diabetes and body 
weight management.  Suitable sweeteners include 
aspartame, saccharin, acesulfame potassium, sucralose 
and Rebaudioside A Erythritol. The inclusion of sugar 
alcohols e.g. sorbitol, is not recommended as they 
contribute 2 kcal/g and are commonly found in diabetic 
chocolate which is high in energy density and offers no 
advantages in managing weight loss.
Alcohol
Alcohol contributes a significant amount of calories (7 
kcal/g) in a diet. Moreover, many people with type 2 
diabetes are overweight or obese, hence alcohol intake 
for diabetic patients should be minimised. The general 
recommendation for alcohol intake is ≤ 2 units per day for 
men and ≤ 1 unit per day for women  (1 unit: 350 ml beer, 
150 ml wine, 45 ml spirits)10. Should patients choose to 
have alcohol, they are advised not to drink on an empty 
stomach since it may lead to hypoglycaemic effects. 
Physical activity
Increasing physical activity improves metabolic control 
and reduces body weight. Low level aerobic exercises, 
such as brisk walking for half an hour per day and 
resistance training, are shown to improve insulin 
sensitivity, result in weight loss, increase the feeling of 
well-being, and improve blood pressure and the lipid 
profiles1,3. Patients are generally advised to do more 
than 150 minutes of moderate intensity physical activity 
per week (e.g. walking). 
Conclusion
Since the outcomes of the MNT interventions are 
evident, MNT should be an integral component of 
diabetes prevention, management, and self-management 
education.  For people with type 2 diabetes, increased 
physical activity and substitution of energy-dense food 
sources (e.g. foods high in dietary fat and sugar) with 
carbohydrate foods rich in fibre and low energy density 
will often lead to better diabetic control.
Dietitian is one of the key health care team members in 
aiding patients' diabetic control. Patients should receive 
MNT by dietitians regularly. Consistent reinforcement 
of dietary advice by dietitians as well as other members 
of the multidisciplinary team may motivate patients to 
make sustainable changes. 
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Medical nutrition therapy for Type 1 diabetes
Type 1 diabetes requires a proper dietary management is 
essential, as well as type 2 diabetes, gestational diabetes 
and glucose intolerance. The diet should be adjusted in 
calories to achieve and maintain a desirable body weight 
and near normal blood glucose levels.  Dietary management 
is also directed at reducing the risks and minimising the 
complications of diabetes.
The American Diabetes Guideline suggests adequate amount 
of calories to maintain a growth pattern, and vitamins and 
minerals for good overall health. Carbohydrate, protein, and 
fat should be balanced to maintain optimal glucose levels. 
Spacing meals and snacks should be taken throughout 
the day to balance the activity of the insulin action of the 
individual. To avoid hypoglycaemia, usually 6 to 7 feedings 
a day are needed to control the blood glucose level and meet 
the nutrient requirements.  Carbohydrate needs to be tailored 
to the patient in order to achieve a good blood glucose control 
and normal triglycerides. Protein recommendations are 10% 
to 20% of the total calories, or 0.8g/kg/day for adults according 
to the Recommended Dietary Allowance (RDA). Fat is ideally 
less than 30% of the total calories, however, actual intakes are 
required to be modified, as for some individuals, this may 
be too low. Polyunsaturated fats are suggested from 6% to 
8%, saturated fats are less than 10%, and monounsaturated 
fats are from 6% to 8%. Cholesterol is recommended to be 
consumed at no more than 300 mg/day.1-6
Medical nutrition therapy for gestational 
diabetes mellitus (GDM)
The diet for pregnant women with diabetes usually is a 
healthful, well-balanced eating plan aimed at achieving 
normoglycaemia and meeting the nutritional needs of the 
foetus and mother during the pregnancy. Consistency in meal 
and snack timings as well as consuming a variety of nutrients 
offered through individualised meal planning should be 
emphasised, as this can help to promote normal glycaemia in 
pregnancy and improve maternal and foetal outcomes. 
Calorie requirements for GDM
Calorie consumption should be calculated to promote 
adequate weight gain and foetal-placental growth. The 
American Diabetes Association (ADA) recommends an 
intake of 2,000 to 2,500 kcal/day, which is based on 35 kcal/
kg of present pregnancy weight, but these recommendations 
should be adjusted for each patient based on weight gain 
and blood sugar control.7
A few studies showed that the ADA recommendations 
led to significant weight gain and elevated postprandial 
blood sugar, which required insulin therapy in about 
50% of women. Based on these findings, the researchers 
recommended calculating energy intake based on 30 kcal/kg 
of present pregnancy weight for normal-weight women, 24 
kcal/kg for overweight women, and 12 kcal/kg for morbidly 
obese women.8,9 
A study of  obese women with GDM showed that 
restricting calories to about 1,800/day improved their 
glycaemic control and still promoted foetal and placental 
development.10 However, consuming fewer than 1,800 kcal/
day is not recommended because of the risk of ketonaemia 
and ketonuria, which are associated with childhood 
neurobehavioural complications.11 
Macronutrient requirements for GDM
Medical nutrition therapy with an emphasis on controlling 
carbohydrate intake is considered the first-line therapy and 
often shows efficacy for normalising blood glucose levels in 
GDM patients. Besides, a lower carbohydrate loading in the 
morning and at night is intended to improve blood sugar 
regulation throughout the day and prevent hyperglycaemia 
caused by the nocturnal activity of steroid hormones 
such as cortisol along with other placental hormones that 
promote insulin resistance.12,13 The use of protein-rich foods 
helps to blunt the effects of the carbohydrates on blood 
glucose. These foods also provide calories without increasing 
the carbohydrate content of meals.  Based on the ADA 
recommendations, the macronutrients in pregnancy and 
diabetes are 50% to 60% of daily calories from carbohydrates 
(complex, high fibre), 10% to 20% from protein, and 25% to 
30% from fat (less than 10% saturated).13
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TUE
Mr. Andy LAW
Tel.: 9133 7281
1 CME point15
HKMA Tai Po Community Network – ESC/ESH Guidelines: Focus on Vasodilator 
Beta-blockers
Organiser: HKMA Tai Po Community Network, Speaker: Dr. KWOK Miu Fong, Jennifer, 
Venue: Chiu Chow Garden Restaurant, Tai Po
1:45 pm
THU
HKMA CME Dept
Tel: 2527 8452
2.5 CME points17
MPS Workshop – Mastering Shared Decision Making
Organisers: Hong Kong Medical Association & Medical Protection Society, Speaker: Dr. Fung 
Shu Yan, Anthony, Venue: Eaton Hotel
6:30 pm
Ms. Nancy CHAN 
Tel: 2527 8898 
FMSHK Executive Committee Meeting
Organiser: The Federation of Medical Societies of Hong Kong, Venue: Council Chamber, 4/F, 
Duke of Windsor Social Service Building, 15 Hennessy Road, Wanchai, Hong Kong
8:00 pm
SUN
Ms. Dorothy KWOK
Tel: 2527 828513 HKMA Tennis Tournament 2013Organiser: The Hong Kong Medical Association, Chairman: Dr. CHIN Chu Wah, Venue: Kowloon Tong Club8:00 pm
WED
Ms. Hana
Tel: 2527 8285
1 CME point16 HKMA Central, Western & Southern Community Network - A Modern Understanding in the Management of Acute PainOrganiser: HKMA Central, Western & Southern Community Network, Speaker: Dr. Wong Kar 
Fai, Richard, Venue: HKMA Central Premises, Dr. Li Shu Pui Professional Education Centre, 
2/F, Chinese Club Building, 21-22 Connaught Road Central, Hong Kong
1:00 pm
SAT
HKMA CME Dept
Tel: 2527 8452
2.5 CME points19 HKMA CME – Seminar on Infectious DiseasesOrganisers: Hong Kong Medical Association, HK Society for Infectious Diseases, Princess Margaret Hospital & Infectious Disease Centre, Speakers: Dr. LUK Chi Kong, David, Dr. 
KWAN Chi Keung, Dr. LUNG, David Christopher & Dr. SO Man Kit, Thomas, Venue: Lecture 
theatre, 7/F, Block H, Princess Margaret Hospital, 2-10, Princess Margaret Hospital Road, Lai 
Chi Kok, Kowloon
1:30 pm
SAT
Ms. Candy YUEN
Tel: 2527 8285
8 CME points12 15th Beijing/Hong Kong Medical Exchange ConferenceOrganiser: The Hong Kong Medical Association, Chairman: Dr. TSE Hung Hing, Venue: Changsha, Hunan1:00 pm(13)
THU
Ms. Vinki CHEUNG
Tel.: 3189 8734
1 CME point10 HKMA New Territories West Community Network - Advance Prevention on Measles, Mumps, Rubella and Varicella in the CommunityOrganiser: HKMA New Territories West Community Network, Speaker: Dr. SIT Sou Chi, 
Venue: Maxim's Palace Chinese Restaurant, Tuen Mun
Ms. Candice TONG
Tel: 2527 8285
HKMA Hong Kong East Community Network - Update on Treatment of Heavy Menstrual Bleeding
Organiser: HKMA Hong Kong East Community Network, Chairman: Dr. YIP Yuk Pang, 
Kenneth, Speaker: Dr. YEO Lee Kung, Evelyn, Venue: HKMA Head Office (5/F., Duke of 
Windsor Social Service Building, 15 Hennessy Road, Hong Kong)
1:00 pm
1:00 pm
HKMA CME Dept
Tel: 2527 8452
1 CME point
HKMA Structured CME Programme with Hong Kong Sanatorium & Hospital Year 2013 – 
Update of IBS
Organisers: Hong Kong Medical Association & Hong Kong Sanatorium & Hospital, Speaker: 
Dr. Chan On On, Annie, Venue: Function Room A, HKMA Dr. Li Shu Pui Professional 
Education Centre, 2/F, Chinese Club Building, 21-22 Connaught Road Central, Hong Kong
2:00 pm
HKMA CME Dept
Tel: 2527 8452
2.5 CME points
MPS Workshop - Mastering Your Risk
Organisesr: Hong Kong Medical Association & Medical Protection Society, Speaker: Dr. Hau 
Kwun Cheung, Venue: HKMA Dr. Li Shu Pui Professional Education Centre, 2/F, Chinese 
Club Building, 21-22 Connaught Road, Central, Hong Kong
6:30 pm
FRI
Ms. Candice TONG
Tel: 2527 8285
1 CME point4 Blood Pressure Control in Chronic Kidney DiseaseOrganiser: HKMA Kowloon City Community Network, Speaker: Dr. Ho Chung Ping, Venue: Spotlight Recreation Club - Hung Hom1:00 pm
TUE
Miss Hana YEUNG
Tel: 2527 82858
HKMA Kowloon West Community Network - Management of Type 2 Diabetic Patients with 
Comorbidities
Organiser: HKMA Kowloon West Community Network, Speaker: Dr. CHAN Wing Bun, 
Venue: Panda Hotel, Tsuen Wan
1:00 pm
MON
Ms. Tammy HUNG
Tel: 9609 6064
1 CME point7 Fournier's GangreneOrganiser: Hong Kong Urological Association, Chairman: Dr. NGAI Ho Yin, Speaker: Dr. Terrilyn PUN, Venue: Multi-disciplinary Simulation and Skills Centre, 4/F, Block F, QEH 7:30 pm
Ms. Nancy CHAN 
Tel: 2527 8898 
FMSHK Officers’ Meeting
Organiser: The Federation of Medical Societies of Hong Kong, Venue: Gallop, 2/F, Hong Kong 
Jockey Club Club House, Shan Kwong Road, Happy Valley, Hong Kong 
8:00 pm
Ms. Christine WONG
Tel: 2527 8285
HKMA Council Meeting
Organiser: The Hong Kong Medical Association, Chairman: Dr. TSE Hung Hing, Venue: HKMA 
Head Office (5/F, Duke of Windsor Social Service Building, 15 Hennessy Road, Hong Kong)
8:00 pm
THU
HKMA CME Dept
Tel: 2527 8452
2.5 CME points3 MPS Workshop – Mastering Shared Decision MakingOrganisers: Hong Kong Medical Association & Medical Protection Society, Speaker: Dr. Fung Shu Yan, Anthony, Venue: HKMA Dr. Li Shu Pui Professional Education Centre, 2/F, Chinese 
Club Building, 21-22 Connaught Road, Central, Hong Kong
6:30 pm
SUN
Mr. Andie HO
Tel: 2527 82856 HKMA Swimming Gala 2013Organiser: The Hong Kong Medical Association, Chairman: Dr. IP Man Ho, Venue: HKPU Michael Clinton Swimming Pool1:00 pm
WED
Miss Hana YEUNG
Tel: 2527 8285
1 CME point9 HKMA Central, Western & Southern Community Network - Third Session of the Certificate Course on Dermatology 2013 - Eczema and BeyondOrganiser: HKMA Central, Western & Southern Community Network, Speaker: Dr. SHIH Tai 
Cho, Venue: Central
1:00 pm
Dr. Gilberto LEUNG
Tel: 2255 3368
1.5 CME points
Hong Kong Neurosurgical Society Monthly Academic Meeting –Recent advances in paediatric 
neuro-oncology
Organiser: Hong Kong Neurosurgical Society, Chairman: Dr. Gilberto Leung, Speaker: Prof. 
Godfrey CF CHAN, Venue: Seminar Room, Ground Floor, Block A, Queen Elizabeth Hospital
7:30 am
Ms. Dorothy KWOK
Tel: 2527 8285
HKMA Tennis Tournament 2013
Organiser: The Hong Kong Medical Association, Chairman: Dr. CHIN Chu Wah, Venue: 
Kowloon Tong Club
8:00 pm
WED
Miss Queenie TSANG
Tel.: 2964 2966
1 CME point2 HKMA Shatin Doctors Network - Diabetic Nephropathy Management 123Organiser: HKMA Shatin Doctors Network, Chairman: Dr. MAK Wing Kin, Speaker: Dr. HO Chung Ping, MH, JP, Venue: Star Seafood Floating Restaurant, 55-57 Tai Chung Kiu Road, Sha 
Tin, N.T.
Date  / Time Function Enquiry / Remarks
1:00 pm
Ms. Cordy WONG
Tel.: 3513 3087
1.5 CME points
HKMA Kowloon East Community Network – Final Session of the CME Course for Health 
Personnel 2013: Update on Childhood Asthma Management
Organiser: HKMA Kowloon East Community Network, Chairman: Dr. LEUNG Man Fuk, 
Speaker: Dr. CHIU Wa Keung, Venue: Lecture Theatre, G/F, Block P, United Christian 
Hospital, 130 Hip Wo Street, Kwun Tong, Kowloon
1:30 pm
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Public talk on Hypertension
On 14 July 2013, a public talk on hypertension was held at the Federation’s Lecture Hall attended by over 70 participants. 
Aligned with the WHO theme, Hypertension, the Foundation is privileged to organise this educational event on the global 
health issue. The first speaker, Dr. Ben FONG, Specialist in Community Medicine, delivered a talk on the prevention and 
treatment of hypertension. The second speaker, Dr. Ngai Pang WONG, Specialist in Endocrinology, Diabetes and Metabolism, 
delivered a talk on the latest update on hypertensive treatment of diabetes mellitus patients. 
The participants’ attentiveness and active questioning and the informative feedbacks from our speakers helped to complete 
a very successful & interactive public talk. Meanwhile, we would like to express our sincere gratitude to Takeda for their 
generosity to sponsor the event.
SUN
Ms. Dorothy KWOK
Tel: 2527 828520 HKMA Tennis Tournament 2013Organiser: The Hong Kong Medical Association, Chairman: Dr. CHIN Chu Wah, Venue: Kowloon Tong Club
8:00 pm
WED
Miss Hana YEUNG
Tel: 2527 8285
1 CME point23
HKMA Central, Western & Southern Community Network - Fourth Session of the Certificate 
Course on Dermatology 2013 - Recent Advance in Cosmetic Dermatology
Organiser: HKMA Central, Western & Southern Community Network, Speaker: Dr. CHAN 
Hin Lee, Henry, Venue: Central
1:00 pm
SAT19 Ms. Clara TSANGTel: 2354 24402 CME pointsHKMA CME – Refresher Course for Health Care Providers 2013/2014Organisers: The Hong Kong Medical Association, HK College of Family Physicians & Our Lady of Maryknoll Hospital, Speaker: Dr. Cheung Wing I, Veronica, Venue: Training 
Room II, 1/F, OPD Block, Our Lady of Maryknoll Hospital, 118 Shatin Pass Road, Wong Tai 
Sin, Kowloon
2:15 pm
TUE
Ms. Abi LI
Tel.: 8100 6509
1 CME point22 HKMA Tai Po Community Network – Primary Prevention of Allergies: When, Who and How?Organiser: HKMA Tai Po Community Network, Speaker: Prof. LEUNG Tin Fan, Venue: Chiu Chow Garden Restaurant, Tai Po1:00 pm
HKMA CME Dept
Tel: 2527 8452
2.5 CME points
MPS Workshop – Mastering Adverse Outcomes
Organisers: Hong Kong Medical Association & Medical Protection Society, Speaker: Dr. Leung 
Kwok Ling, Ares, Venue: HKMA Dr. Li Shu Pui Professional Education Centre, 2/F, Chinese 
Club Building, 21-22 Connaught Road, Central, Hong Kong
6:30 pm
THU
Ms. Candice TONG
Tel: 2527 8285
1 CME point24 HKMA Hong Kong East Community Network - Management of Atopic DermatitisOrganiser: HKMA Hong Kong East Community Network, Speaker: Dr. CHAN Tak Yan, Norman, Venue: HKMA Head Office1:00 pm
Miss Hana YEUNG
Tel: 2527 8285
1 CME point
HKMA Kowloon East Community Network - Management of Atopic Dermatits
Organiser: HKMA Kowloon East Community Network, Speaker: Dr. LUK Chi Kong, David, 
Venue: Lei Garden Restaurant, Kwun Tong
1:00 pm
HKMA CME Dept
Tel: 2527 8452
2.5 CME points
MPS Workshop – Mastering Difficult Interactions with Patients
Organisers: Hong Kong Medical Association & Medical Protection Society, Speaker: Dr. Cheng 
Ngai Shing, Justin, Venue: Eaton Hotel
6:30 pm
Ms. Nancy CHAN 
Tel: 2527 8898 
FMSHK Foundation Committee Meeting
Organiser: The Federation of Medical Societies of Hong Kong, Venue: Council Chamber, 4/F, 
Duke of Windsor Social Service Building, 15 Hennessy Road, Wanchai, Hong Kong
8:00 pm
SUN
Ms. Dorothy KWOK
Tel: 2527 828527 HKMA Tennis Tournament 2013Organiser: The Hong Kong Medical Association, Chairman: Dr. CHIN Chu Wah, Venue: Kowloon Tong Club8:00 pm
SAT
HKMA CME Dept
Tel: 2527 8452
2.5 CME points26
MPS Workshop – Mastering Your Risk
Organisers: Hong Kong Medical Association & Medical Protection Society, Speaker: Dr. Lee 
Wai Hung, Danny, Venue: Central
2:30 pm
THU
HKMA CME Dept
Tel: 2527 8452
1 CME point31
HKMACME-New concept of stroke management
Organiser: Hong Kong Medical Association, Speaker: Dr. PANG Ka Hung, Peter, Venue: 
HKMA Dr. LI Shu Pui Professional Education Centre, 2/F. Chinese Club Building, 21-22 
Connaught Road Central, Hong Kong
1:00 pm
Miss Nadia HO
Tel: 2527 8285
The 4th GHM Sports Meet
Organiser: Macau Chinese Medical Association, Chairman: Dr. TSE Hung Hing, Venue: Macau(27)
Date  / Time Function Enquiry / Remarks
Upcoming Meeting
Gast o intestinal dysfunction : integrative management
Organiser: Hong Kong Association for Integration of Chinese-Western Medicine, Venue: Lecture Theatre, 10/F, Yu Chun Keung 
Memorial Medical Centre, Kwong Wah Hospit l, Kowloon,  Enquiry?Miss YC YEUNG   Tel: 3119 1858    2.5 CME points
6/11/2013
International Scientific Congr ss- Manpower nee s in medicine: moving with the times
Organ ser: Hong Kong Academy of Medicine, Venu : Academy Building, Enquiry?Secretariat Tel: 2871 8787
8-10/11/2013
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Answers to Dermatological Quiz
Answers:
1.
2.
This middle aged man developed this persistent net-
like reticulated mottled erythematous pattern at his 
lower limbs is compatible with livedo reticularis.  It is a 
common physiological finding resulted from a vasospastic 
response to cold exposure. Among normal healthy 
individuals, the predisposition to livedo reticularis varies. 
If it is persistently present as in our patient, it can also be 
a reflection of a number of underlying systemic diseases. 
Differential diagnoses include heat induced erythema ab 
igne and other reticulated dermatoses such as reticulated 
erythematous mucinosis and poikilodermatous mycosis 
fungoides which should have epidermal changes with 
telangiectasia.
Livedo reticularis is a clinical sign and does not require 
any treatment per se. It is unresponsive to treatments such 
as vascular laser therapy or vasodilatory medications. 
Underlying causes require identification and appropriate 
treatment.  In our patient, acquired livedo reticularis with 
persistent changes is suggestive of underlying diseases. 
It can be due to vasospasm associated with autoimmune 
connective diseases (e.g. in our patient with SLE with 
positive ANA and anti DNA) or Raynaud’s disease/
phenomenon.  It can be due to reduced intravascular 
blood flow (e.g. due to thrombocythaemia, polycythaemia 
rubra vera, presence of cryoglobulinaemia or presence 
of hypercoagulability state due to antiphospholipid 
syndrome).  It can also be due to vessel wall pathology 
(e.g. vasculitis as a result of cutaneous polyarteritis 
nodosa or autoimmune connective tissue disease-
associated vasculitis such as rheumatoid arthritis).  Vessel 
obstruction due to embolic events (e.g. cholesterol emboli 
or septic emboli) rarely presents as livedo reticularis. 
Relevant investigations, as guided by the relevant clinical 
presentation, to exclude the above causes should be 
done to define the underlying diseases so that specific 
treatment can be given.
Dr. Ka-ho LAU 
MBBS(HK), FRCP(Glasg, Edin), FHKCP, FHKAM(Med)
Private dermatologist
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